natriuretic agents

Summary

Summary: Endogenous or exogenous chemicals that regulate the WATER-ELECTROLYTE BALANCE in the body. They consist of peptides and non-peptide compounds.

Top Publications

  1. ncbi Effects of intravenous nesiritide on human coronary vasomotor regulation and myocardial oxygen uptake
    Andrew D Michaels
    Division of Cardiology, Department of Medicine, University of California at San Francisco Medical Center, 505 Parnassus Ave, Box 0124, San Francisco, Calif 94143 0124, USA
    Circulation 107:2697-701. 2003
  2. ncbi Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials
    Jonathan D Sackner-Bernstein
    Clinical Scholars Program, Division of Cardiology, North Shore University Hospital, Manhasset, NY 11030, USA
    JAMA 293:1900-5. 2005
  3. ncbi [Medical and ventilatory treatment of acute heart failure]
    Anders Hodt
    Nasjonalforeningen for folkehelsen, Det norske hjerte karrådet og Hjerteavdelingen, Aker universitetssykehus, 0514 Oslo
    Tidsskr Nor Laegeforen 126:749-52. 2006
  4. ncbi Risk of death associated with nesiritide in patients with acutely decompensated heart failure
    Keith D Aaronson
    JAMA 296:1465-6. 2006
  5. ncbi Prophylactic nesiritide does not prevent dialysis or all-cause mortality in patients undergoing high-risk cardiac surgery
    A Ahsan Ejaz
    Division of Nephrology, Hypertension and Transplantation, University of Florida, Gainesville, FL 32610 0224, USA
    J Thorac Cardiovasc Surg 138:959-64. 2009
  6. ncbi Nesiritide following maze and mitral valve surgery
    Thomas M Beaver
    Division of Thoracic and Cardiovascular Surgery, University of Florida, Gainesville, Florida 36210 0286, USA
    J Card Surg 23:431-6. 2008
  7. ncbi Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery:the NAPA Trial
    Robert M Mentzer
    Division of Cardiothoracic Surgery, Department of Surgery, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    J Am Coll Cardiol 49:716-26. 2007
  8. ncbi Nesiritide - not verified
    Eric J Topol
    Case Western Reserve University, Cleveland, USA
    N Engl J Med 353:113-6. 2005
  9. ncbi Pharmacological therapy of acute cardiogenic pulmonary oedema in the emergency department
    Colin A Graham
    Southern General Hospital, Glasgow G51 4TF, Scotland, UK
    Emerg Med Australas 16:47-54. 2004
  10. ncbi Controversy and conflict in the treatment of acute decompensated heart failure: nesiritide as evidence-based treatment
    Mark A Munger
    Department of Pharmacotherapy and Internal Medicine, University of Utah, Salt Lake City, Utah 84112, USA
    Pharmacotherapy 27:619-25. 2007

Research Grants

Detail Information

Publications178 found, 100 shown here

  1. ncbi Effects of intravenous nesiritide on human coronary vasomotor regulation and myocardial oxygen uptake
    Andrew D Michaels
    Division of Cardiology, Department of Medicine, University of California at San Francisco Medical Center, 505 Parnassus Ave, Box 0124, San Francisco, Calif 94143 0124, USA
    Circulation 107:2697-701. 2003
    ..Nesiritide, recombinant human B-type natriuretic peptide, has been shown to be efficacious in the treatment of decompensated heart failure. The effects of intravenous nesiritide on the human coronary vasculature have not been studied...
  2. ncbi Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials
    Jonathan D Sackner-Bernstein
    Clinical Scholars Program, Division of Cardiology, North Shore University Hospital, Manhasset, NY 11030, USA
    JAMA 293:1900-5. 2005
    ..Nesiritide improves symptoms in patients with acutely decompensated heart failure compared with placebo and appears to be safer than dobutamine. Its short-term safety relative to standard diuretic and vasodilator therapies is less clear...
  3. ncbi [Medical and ventilatory treatment of acute heart failure]
    Anders Hodt
    Nasjonalforeningen for folkehelsen, Det norske hjerte karrådet og Hjerteavdelingen, Aker universitetssykehus, 0514 Oslo
    Tidsskr Nor Laegeforen 126:749-52. 2006
    ..In 2005 the European Society of Cardiology published new guidelines on diagnosis and treatment. Also, new therapies have been introduced recently, giving rise to changes in therapeutic concepts...
  4. ncbi Risk of death associated with nesiritide in patients with acutely decompensated heart failure
    Keith D Aaronson
    JAMA 296:1465-6. 2006
  5. ncbi Prophylactic nesiritide does not prevent dialysis or all-cause mortality in patients undergoing high-risk cardiac surgery
    A Ahsan Ejaz
    Division of Nephrology, Hypertension and Transplantation, University of Florida, Gainesville, FL 32610 0224, USA
    J Thorac Cardiovasc Surg 138:959-64. 2009
    ....
  6. ncbi Nesiritide following maze and mitral valve surgery
    Thomas M Beaver
    Division of Thoracic and Cardiovascular Surgery, University of Florida, Gainesville, Florida 36210 0286, USA
    J Card Surg 23:431-6. 2008
    ....
  7. ncbi Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery:the NAPA Trial
    Robert M Mentzer
    Division of Cardiothoracic Surgery, Department of Surgery, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    J Am Coll Cardiol 49:716-26. 2007
    ..The purpose of this study was to determine the role nesiritide might play in patients with left ventricular dysfunction undergoing coronary artery bypass grafting (CABG) using cardiopulmonary bypass (CPB)...
  8. ncbi Nesiritide - not verified
    Eric J Topol
    Case Western Reserve University, Cleveland, USA
    N Engl J Med 353:113-6. 2005
  9. ncbi Pharmacological therapy of acute cardiogenic pulmonary oedema in the emergency department
    Colin A Graham
    Southern General Hospital, Glasgow G51 4TF, Scotland, UK
    Emerg Med Australas 16:47-54. 2004
    ..The evidence base for 'routine therapy' in the ED is considered. The review also briefly considers emerging pharmacological therapies that may have an impact on future management of cardiogenic pulmonary oedema...
  10. ncbi Controversy and conflict in the treatment of acute decompensated heart failure: nesiritide as evidence-based treatment
    Mark A Munger
    Department of Pharmacotherapy and Internal Medicine, University of Utah, Salt Lake City, Utah 84112, USA
    Pharmacotherapy 27:619-25. 2007
    ....
  11. ncbi [Natriuretic peptides in heart failure]
    Luis Almenar Bonet
    Unidad de Insuficiencia Cardiaca y Trasplante, Servicio de Cardiologia, Hospital Universitario La Fe, Valencia, Spain
    Rev Esp Cardiol 6:15-26. 2006
    ....
  12. ncbi Advances in the management of acute and chronic decompensated heart failure
    Sandra L Lowery
    CCMI Associates, 1163 New Boston Road, Francestown, NH 03043, USA
    Lippincotts Case Manag 9:S1-15; quiz S16-7. 2004
    ..To date the typical treatment of acute decompensation has been based in the hospital and woefully inadequate in promoting any long-term medical stability...
  13. ncbi Decompensated heart failure: is there a role for the outpatient use of nesiritide?
    Clyde W Yancy
    University of Texas Southwestern Medical Center, Department of Internal Medicine Cardiology Division, CS7 102, 5323 Harry Hines Boulevard, Dallas, TX 75235, USA
    Congest Heart Fail 10:230-6. 2004
    ..Such an approach, once validated, should be integrated into an evidence-based HF disease management program...
  14. ncbi Safety and efficacy of nesiritide for acute decompensated heart failure: recent literature and upcoming trials
    Brian Hiestand
    Department of Emergency Medicine, The Ohio State University, 149 Means Hall, 1654 Upham Drive, Columbus, OH 43210, USA
    Curr Cardiol Rep 9:182-6. 2007
    ..We review the recent evidence regarding the efficacy and safety profile of nesiritide, and discuss upcoming trials designed to address concerns regarding safety and the comparative efficacy of nesiritide...
  15. ncbi Nesiritide for acute decompensated heart failure: does the benefit justify the risk?
    Jonathan Sackner-Bernstein
    Clinilabs, Inc, 423 West 55th Street, 4th Floor, New York, NY 10019, USA
    Curr Cardiol Rep 9:187-93. 2007
    ..We conclude that with nesiritide, the risks of therapy outweigh the benefits demonstrated to date...
  16. ncbi Alterations in the natriuretic hormone system related to cardiopulmonary bypass in infants with congestive heart failure
    J M Costello
    Division of Cardiology, Children s Memorial Hospital, The Feinberg School of Medicine at Northwestern University, Chicago, IL 60614 3394, USA
    Pediatr Cardiol 25:347-53. 2004
    ....
  17. ncbi Nesiritide therapy for acute heart failure
    Alice Johnson-Davis
    Jeanette Cantrell Rudy School of Nursing, Cumberland University, Lebanon, TN, USA
    J Perianesth Nurs 18:386-91. 2003
    ..One of the newest pharmacological therapies for heart failure is nesiritide. The PACU nurse's vital role in the early recognition and early intervention of heart failure may include the administration of this agent...
  18. ncbi Nesiritide in perspective: evolving approaches to the management of acute decompensated heart failure
    Roger M Mills
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Drugs Today (Barc) 39:767-74. 2003
    ..As with most advances, the process of rolling back the frontiers of knowledge has posed even more questions. However, we must not overlook the progress to date, simply because all of the answers are not yet available...
  19. ncbi Treatment of the acute decompensation of heart failure: efficacy and pharmacoeconomics of early initiation of therapy in the emergency department
    Charles L Emerman
    Department of Emergency Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Rev Cardiovasc Med 4:S13-20. 2003
    ..This article reviews the initial management of ADHF, the role of early initiation of vasodilator therapy, and the pharmacoeconomics of nesiritide treatment...
  20. ncbi New and emerging drug therapies for the management of acute heart failure
    H Krum
    Department of Medicine, Monash University Central and Eastern Clinical School, Alfred Hospital, Melbourne, Victoria, Australia
    Intern Med J 33:515-20. 2003
    ..This review will examine the key emerging therapies for acute heart failure, in light of available pathophysiological and clinical evidence...
  21. ncbi Nesiritide use for critically ill children awaiting cardiac transplantation
    R Sehra
    Loma Linda University, Del Mar, CA 92014, USA
    Pediatr Cardiol 27:47-50. 2006
    ..This study aimed to explore the effects of nesiritide in children awaiting cardiac transplantation...
  22. ncbi Treatment options for acute decompensated heart failure
    Mary Ross Southworth
    University of Illinois at Chicago, 840 S Wood Street M C 715, Chicago, IL 60612, USA
    Am J Health Syst Pharm 60:S7-15. 2003
    ..It is important to remember that therapy for ADHF should not replace chronic oral heart failure therapy, nor should focus on prevention of ADHF episodes be lost...
  23. ncbi Effect of nesiritide (human b-type natriuretic peptide) and dobutamine on heart rate variability in decompensated heart failure
    Doron Aronson
    Division of Cardiology, Rambam Medical Center, Haifa, Israel
    Am Heart J 148:e16. 2004
    ..We sought to assess the effects of nesiritide compared with dobutamine on time-domain indices of heart rate variability (HRV) in patients with decompensated CHF...
  24. ncbi The natriuretic peptides in cardiovascular medicine
    Vijaya K Munagala
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Curr Probl Cardiol 29:707-69. 2004
    ..The clinical literature regarding the use of recombinant BNP for the treatment of HF is reviewed, underscoring current gaps in our knowledge regarding the indications for and benefits of this novel agent...
  25. ncbi The use of recombinant human B-type natriuretic peptide (nesiritide) in the management of acute decompensated heart failure
    W D Strain
    National Heart and Lung Institute, Faculty of Medicine, Imperial College London at St Mary s, Norfolk Place, London, UK
    Int J Clin Pract 58:1081-7. 2004
    ..When compared to dobutamine, the increased acquisition costs of nesiritide are completely offset by reduced intensity of hospital admissions and reduced readmission rate at 3 weeks...
  26. ncbi Acute decompensated heart failure: best evidence and current practice
    R Mehta
    Unit of Cardiovascular Diseases, The Ohio State University, Columbus, OH, USA
    Minerva Cardioangiol 53:537-47. 2005
    ....
  27. ncbi Optimizing outcomes in the patient with acute decompensated heart failure
    Mandeep R Mehra
    Division of Cardiology, Department of Medicine, University of Maryland, Baltimore, MD, USA
    Am Heart J 151:571-9. 2006
    ....
  28. ncbi Nesiritide for pulmonary arterial hypertension with decompensated cor pulmonale
    Martha S Kingman
    Pulmonary Hypertension Group, Pulmonary Hypertension Clinic, Cardiovascular Institute, St Paul University Hospital, University of Texas Southwestern Medical Center, Dallas, TX 75235, USA
    Prog Cardiovasc Nurs 20:168-72. 2005
    ..A detailed case report is presented followed by the evaluation of a series of 11 cases occurring in eight patients from December 2002 through April 2004...
  29. ncbi Pharmacoeconomic modeling of nesiritide versus dobutamine for decompensated heart failure
    Tobias Gerhard
    Department of Pharmacy Health Care Administration, University of Florida, P O Box 100496, Gainesville, FL 32610, USA
    Pharmacotherapy 26:34-43. 2006
    ..To model the cost-effectiveness of nesiritide compared with dobutamine in patients with decompensated heart failure...
  30. ncbi A review of the natriuretic hormone system's diagnostic and therapeutic potential in critically ill children
    John M Costello
    Division of Cardiac Intensive Care, Department of Cardiology, Children s Hospital Boston and Harvard Medical School, Boston, MA, USA
    Pediatr Crit Care Med 7:308-18. 2006
    ..To review the natriuretic hormone system and discuss its diagnostic, prognostic, and therapeutic potential in critically ill children...
  31. ncbi A prospective evaluation of nesiritide in the treatment of pediatric heart failure
    J L Jefferies
    Division of Pediatric Cardiology, Texas Children s Hospital, 6621 Fannin, MC 19345 C, Houston, TX 77030, USA
    Pediatr Cardiol 27:402-7. 2006
    ..It is associated with decreased thirst and improved urine output and functional status, and it may be efficacious in the treatment of pediatric HF...
  32. ncbi Nesiritide: harmful or harmless?
    Michael P Dorsch
    Department of Pharmacy Services, University of Michigan Hospitals and Health Clinics, Ann Arbor, Michigan 48109 0008, USA
    Pharmacotherapy 26:1465-78. 2006
    ..Until these data are available, nesiritide use should be limited...
  33. ncbi Nesiritide in infants and children with congestive heart failure
    William T Mahle
    Sibley Heart Center, Children s Healthcare of Atlanta, and the Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA
    Pediatr Crit Care Med 6:543-6. 2005
    ..The role of nesiritide in pediatric heart failure has not been examined. In the present study, we reviewed our initial experience with nesiritide in children with primary heart failure or low cardiac output after heart surgery...
  34. ncbi Right heart overload contributes to cardiac natriuretic hormone elevation in patients with heart failure
    Claudio Passino
    Institute of Clinical Physiology, National Research Council, Pisa, Italy
    Int J Cardiol 104:39-45. 2005
    ..We assessed the hypothesis that right ventricular (RV) overload might significantly contribute to plasma elevation of cardiac natriuretic hormones in patients with heart failure...
  35. ncbi Intravenous nesiritide in acute heart failure
    Mark A Knox
    Department of Family Medicine, University of Pittsburgh Medical Center Presbyterian Shadyside, Pittsburgh, Pennsylvania 15232, USA
    Am J Ther 12:233-7. 2005
    ..Patients who received nesiritide incurred significantly higher charges for medical care, but nesiritide did not affect length of stay, readmission rates, or mortality...
  36. ncbi Clinical and hemodynamic effects of nesiritide (B-type natriuretic peptide) in patients with decompensated heart failure receiving beta blockers
    William T Abraham
    Division of Cardiovascular Medicine, The Ohio State University, Columbus, OH 43210 1252, USA
    Congest Heart Fail 11:59-64. 2005
    ..Thus, the clinical and hemodynamic benefits and safety of nesiritide are preserved in decompensated congestive heart failure patients receiving chronic beta blockade...
  37. ncbi Effects of standard heart failure therapy and concomitant treatment with intravenous furosemide or inotropes (dobutamine, dopamine, and/or milrinone) on renal function and mortality in patients treated with nesiritide
    Shaun Kurien
    Department of Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Am J Cardiol 98:1627-30. 2006
    ....
  38. ncbi Short and long-term mortality with nesiritide
    Rohit R Arora
    The Department of Medicine, The Chicago Medical School, Chicago, IL 60064, USA
    Am Heart J 152:1084-90. 2006
    ..We performed a meta-analysis of 7 available randomized controlled trials to evaluate the short- and long-term risk of death with nesiritide use for acute decompensated heart failure...
  39. ncbi Beneficial effects of early initiation of vasoactive agents in patients with acute decompensated heart failure
    Mitchell T Saltzberg
    Midwest Heart Specialists HeartFailure Program, Midwest Heart Foundation Echocardiographic Core Laboratory, Downers Grove, Illinois, USA
    Rev Cardiovasc Med 5:S17-27. 2004
    ..Nesiritide, a human recombinant B-type natriuretic peptide, is a safe, effective vasodilator that can be easily used early in the emergency department to improve outcomes in ADHF...
  40. ncbi Current and novel pharmacological approaches to renal insufficiency in heart failure
    V Hindnavis
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44195, USA
    Minerva Cardioangiol 54:753-62. 2006
    ..These include natriuretic peptides and other vasodilators, adenosine receptor antagonists, and vasopressin receptor antagonists all currently undergoing late-stage clinical trials...
  41. ncbi Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial
    Bradley A Bart
    Minnesota Heart Failure Consortium, Minneapolis, Minnesota, USA
    J Am Coll Cardiol 46:2043-6. 2005
    ..The purpose of this research was to assess the safety and efficacy of ultrafiltration (UF) in patients admitted with decompensated congestive heart failure (CHF)...
  42. ncbi Sustained use of nesiritide to aid in bridging to heart transplant
    James A Hill
    Heart Failure Transplantation Program, Division of Cardiology, University of Florida, Gainesville, Florida, USA
    Clin Cardiol 26:211-4. 2003
    ..This suggests that new strategies for pretransplant management may be needed...
  43. ncbi Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure
    Dalane W Kitzman
    Section of Cardiology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC 27157 1045
    JAMA 288:2144-50. 2002
    ..However, the pathophysiology of this disorder, presumptively termed diastolic heart failure (DHF), is not well characterized and it is unknown whether it represents true heart failure...
  44. ncbi Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study
    Andrew J Burger
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass 02215, USA
    Am Heart J 144:1102-8. 2002
    ..In this randomized, multicenter trial, we compared the safety and clinical effectiveness of the cardiac hormone nesiritide (human B-type natriuretic peptide) with dobutamine in hospitalized patients with decompensated CHF...
  45. ncbi New advances and novel treatments in heart failure
    Andrew Lee Smith
    Center for Heart Failure Therapy, Emory University Hospital, Atlanta, GA, USA
    Crit Care Nurse . 2003
    ....
  46. ncbi Controversy and conflict in the treatment of acute decompensated heart failure: limited role for nesiritide
    John A Noviasky
    Department of Pharmacy, St Elizabeth Medical Center, Utica, New York 13501, USA
    Pharmacotherapy 27:626-32. 2007
    ..After review of this article, the reader should be able to answer the question--if nesiritide had never been approved for use in patients with ADHF, would we have missed it?--with a negative reply...
  47. ncbi Economic implications of nesiritide versus dobutamine in the treatment of patients with acutely decompensated congestive heart failure
    Gregory de Lissovoy
    MEDTAP International, Inc, Bethesda, Maryland 20814, USA
    Am J Cardiol 92:631-3. 2003
    ..Results indicate that the acquisition cost of nesiritide is fully offset by decreased hospital costs...
  48. ncbi Nesiritide (Natrecor): a new treatment for acutely decompensated congestive heart failure
    Katberine Colbert
    The Southside Regional Medical Center, Petersburg, VA, USA
    Crit Care Nurs Q 26:40-4. 2003
    ..The neurohormonal effects of endogenous BNP are reproduced by nesiritide. Indications, dosing, administration, and review of clinical trials are presented in this article...
  49. ncbi "BNP" for heart failure: role of nesiritide in cardiovascular therapeutics
    Roger M Mills
    Kaufman Center for Heart Failure, Department of Cardiology, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Congest Heart Fail 8:270-3. 2002
    ..In this review, the authors summarize the currently available data regarding the use of nesiritide, and offer recommendations for its use based on our experience with the compound in clinical trials...
  50. ncbi Using BNP to diagnose, manage, and treat heart failure
    Robert E Hobbs
    Department of Cardiovascular Medicine, Kaufman Center for Heart Failure, The Cleveland Clinic, Cleveland Clinic Foundation, OH 44195, USA
    Cleve Clin J Med 70:333-6. 2003
    ..A synthetic formulation of BNP (nesiritide) is used to treat decompensated heart failure, resulting in improved hemodynamics and symptoms...
  51. ncbi Rapid optimization: strategies for optimal care of decompensated congestive heart-failure patients in the emergency department
    W Frank Peacock
    Department of Emergency Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Rev Cardiovasc Med 3:S41-8. 2002
    ....
  52. ncbi Pharmacologic therapies for acutely decompensated heart failure
    Gregg C Fonarow
    Division of Cardiology, UCLA School of Medicine, Los Angeles, California, USA
    Rev Cardiovasc Med 3:S18-27. 2002
    ....
  53. ncbi Administration of brain natriuretic peptide improves cardiac function following operations using extracorporeal circulation in an animal model
    Dorothee H L Bail
    Department of Thoracic, Cardiac and Vascular Surgery, University of Tubingen, Hoppe Seyler Str 3, D 72076 Tubingen, Germany
    Clin Sci (Lond) 112:315-24. 2007
    ..In conclusion, administration of BNP is highly effective in treating post-ischaemic heart failure following ECC. Haemodynamics are greatly improved, and there is almost no need for pharmacological support...
  54. ncbi Atrial natriuretic factor: neuromodulator of the central nervous system regulation of blood pressure
    E R Levin
    Department of Medicine, Long Beach Veterans Hospital, CA 90822
    Am J Hypertens 2:594-8. 1989
    ..Experiments from other laboratories indicate that central ANF may modulate the pressor effects of centrally acting angiotensin II.(ABSTRACT TRUNCATED AT 250 WORDS)..
  55. ncbi Aldosterone biosynthesis, regulation, and classical mechanism of action
    Gordon H Williams
    Division of Endocrinology, Diabetes and Hypertension, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Heart Fail Rev 10:7-13. 2005
    ..Aldosterone's biosynthesis appears to be regulated in these tissues similar to what occurs in the adrenal cortex. The role of this extra adrenal aldosterone production in health and disease is as of yet undetermined...
  56. pmc mPGES-1 deletion impairs aldosterone escape and enhances sodium appetite
    Zhanjun Jia
    Department of Internal Medicine, University of Utah and Veterans Affairs Medical Center, Salt Lake City, Utah 84132, USA
    Am J Physiol Renal Physiol 299:F155-66. 2010
    ..Together, these results suggest an important role of mPGES-1 in antagonizing the sodium-retaining action of Aldo at the levels of both the central nervous system and the kidney...
  57. ncbi Membrane guanylate cyclase signal transduction system
    R K Sharma
    UMDNJ, SOM, Department of Cell Biology, New Jersey 08084, USA
    Indian J Biochem Biophys 34:40-9. 1997
    ..This review will briefly discuss the fascinating, albeit turbulent, history of this signal transduction field, which will be followed by its current status and finally the direction it is heading...
  58. ncbi Cerebral salt wasting syndrome: review
    M Cerda-Esteve
    Endocrinology Department, Hospital Universitari del Mar, Universitat Autonoma de Barcelona, Barcelona, Spain
    Eur J Intern Med 19:249-54. 2008
    ..The essential point is the volemic state. It is necessary to rule out other intermediate causes. Treatment requires volume replacement and maintenance of a positive salt balance. Mineral corticoids may be useful in complicated cases...
  59. ncbi Natriuresis of fasting: the possible role of leptin-neuropeptide Y system
    E Sulyok
    County Children s Hospital, H 7624 Pecs, Hungary
    Med Hypotheses 56:629-33. 2001
    ..4. This sequence of events implies that NPY contributes to natriuresis that occurs in response to fasting...
  60. ncbi Antihypertensive action of beta-adrenoceptor blocking drugs. The role of intrarenal mechanisms
    H A Struyker-Boudier
    Department of Pharmacology, University of Limburg, Maastricht, The Netherlands
    Am J Hypertens 2:237S-240S. 1989
    ..The possible mechanisms of renal vasodilatation of tertatolol are reviewed. It is concluded that the shift of the renal pressure-diuresis curve is an essential feature in the mode of long-term antihypertensive action of beta-blockers...
  61. ncbi Gene expression profile during acute rejection in rat-to-mouse concordant cardiac xenograft by means of DNA microarray
    Akio Saiura
    Department of Molecular Biology and Medicine, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan
    Transpl Int 15:535-40. 2002
    ..In addition to known genes, many expressed sequence tags were induced in the xenografts. We identified a group of genes, including Mac-1 induced specifically in xenografts, as well as many new genes upregulated in xenografts...
  62. ncbi Aliskiren
    Morris J Brown
    University of Cambridge, Cambridge, UK
    Circulation 118:773-84. 2008
    ..understanding of the renin system will maximize its value, for instance, by encouraging greater use of natriuretic agents in patients with resistant hypertension to render their hypertension renin dependent...
  63. ncbi Cerebral salt wasting syndrome
    M R Harrigan
    Department of Surgery, Section of Neurosurgery, University of Michigan, Ann Arbor, Michigan, USA
    Crit Care Clin 17:125-38. 2001
    ..Future investigation is needed to better define the incidence of CSW in patients with intracranial disease, identify other disorders that can lead to CSW, and elucidate the mechanisms underlying this syndrome...
  64. pmc Increased renal phosphodiesterase-5 activity mediates the blunted natriuretic response to a nitric oxide donor in the pregnant rat
    Jennifer M Sasser
    Dept of Physiology and Functional Genomics, Univ of Florida, PO Box 100274, Gainesville, FL 32610, USA
    Am J Physiol Renal Physiol 299:F810-4. 2010
    ..Therefore, increased intrarenal PDE5 mediates the blunted natriuretic response to NO, and loss of responsiveness to the cGMP-dependent, natriuretic agents may contribute to volume expansion during pregnancy.
  65. ncbi Natriuretic peptide response to dynamic exercise in patients with atrial fibrillation
    Mads D M Engelmann
    Department of Cardiology, Herlev University Hospital, Herlev, Denmark
    Int J Cardiol 105:31-9. 2005
    ..The aim of this study was to investigate plasma ANP and BNP response to exercise in patients with permanent AF and to assess if the response was different from the response in healthy age- and sex-matched control subjects...
  66. pmc Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF
    Robert J Mentz
    Duke University Medical Center, Durham, NC, USA
    Eur J Heart Fail 15:456-64. 2013
    ..To examine the characteristics associated with early dyspnoea relief during acute heart failure (HF) hospitalization, and its association with 30-day outcomes...
  67. ncbi Discovery of a novel sub-class of ROMK channel inhibitors typified by 5-(2-(4-(2-(4-(1H-Tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-one
    Haifeng Tang
    Department of Medicinal Chemistry, Rahway, NJ 07065, United States Department of Ions Channels, Cardiovascular Disease, Rahway, NJ 07065, United States Department of Drug Metabolism and Pharmacology, Rahway, NJ 07065, United States Department of Merck Research Laboratories, Rahway, NJ 07065, United States Electronic address
    Bioorg Med Chem Lett 23:5829-32. 2013
    ..inhibitors were characterized for the first in vivo proof-of-concept biology studies, and results from an acute rat diuresis model confirmed the hypothesis that ROMK inhibitors represent new mechanism diuretic and natriuretic agents.
  68. ncbi Hemodynamic optimization in high-risk mitral valve repairs as a key component in surgical readiness
    Rajan Kanth
    Department of Internal Medicine, Marshfield Clinic, 1000 N Oak Ave, Marshfield, WI 54449, USA
    WMJ 112:69-73. 2013
    ..This case report illustrates the importance of a systemic approach with high-risk surgery, and the use of strategies that optimize key patient factors, including hemodynamics, prior to all elective and urgent procedures...
  69. ncbi Brain natriuretic peptide in heart failure and beyond
    Mohammad M Mowla
    Division of Cardiac Sciences, Department of Medicine, King Abdul Aziz National Guard Hospital, PO Box 2477, Al Ahsa 31982, Kingdom Saudi Arabia
    Saudi Med J 27:1457-61. 2006
    ..This paper reviews the available literature concerning the BNP and N-terminal pro brain-type natriuretic peptide to assess their role in current medical practice...
  70. ncbi Nesiritide in acute decompensated heart failure: a pooled analysis of randomized controlled trials
    William T Abraham
    Division of Cardiovascular Medicine, The Ohio State University, Columbus, Ohio, USA
    Clin Cardiol 33:484-9. 2010
    ..This study used relevant data from all RCTs of nesiritide in ADHF completed as of June 2006 to independently estimate the effect of nesiritide on 30- and 180-day mortality...
  71. pmc Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials
    Gianluigi Savarese
    Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy
    PLoS ONE 8:e58287. 2013
    ..The purpose of this study was to evaluate whether natriuretic peptide-guided therapy, compared to clinically-guided therapy, improves mortality and hospitalization rate in patients with chronic HF...
  72. ncbi The use of nesiritide in the management of acute decompensated heart failure. 2002
    Steven R Kayser
    Department of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco, CA 94143 0622, USA
    Prog Cardiovasc Nurs 22:89-95. 2007
  73. ncbi [BNP or NT-proBNP: "that is the question"]
    C Lebrun
    Service de Biochimie, Centre Hospitalier de Chambery
    Ann Biol Clin (Paris) 65:533-8. 2007
    ..It is clear that all Diagnostics Manufacturers should now propose different cut-off for natriuretic peptides tests according to the degree of patients' renal impairment...
  74. ncbi Acute heart failure: perspectives from a randomized trial and a simultaneous registry
    Justin A Ezekowitz
    Mazankowski Alberta Heart Institute and the University of Alberta, Edmonton, AB, Canada
    Circ Heart Fail 5:735-41. 2012
    ....
  75. pmc C-type natriuretic peptide does not attenuate the development of pulmonary hypertension caused by hypoxia and VEGF receptor blockade
    Brian Casserly
    Department of Medicine, Alpert Medical School of Brown University, Providence, RI 02912, USA
    Life Sci 89:460-6. 2011
    ..The purpose of this study was to determine if CNP is capable of preventing the development of pulmonary hypertension (PH)...
  76. ncbi [Tako-Tsubo syndrome during normal human immunoglobolin perfusion]
    P Gautier
    Unité de réanimation polyvalente et soins intensifs cardiaques, Médecine Interne et Cardiologie, centre hospitalier Jacques Lacarin, Vichy, France
    Ann Cardiol Angeiol (Paris) 60:290-5. 2011
    ..Also, MRI ruled out inflammatory and ischemic cardiac diseases. The most likely diagnosis for us was Tako-Tsubo syndrome in relation with injection of Human Normal Immunoglobulin (Tegeline(®)) according to the Mayo clinic criteria...
  77. ncbi Nesiritide: trials and tribulations
    Rohit R Arora
    Department of Medicine, The Chicago Medical School, Chicago, Illinois, USA
    J Cardiovasc Pharmacol Ther 11:165-9. 2006
    ....
  78. ncbi Perioperative nesiritide versus milrinone in high-risk coronary artery bypass graft patients
    Marcia L Brackbill
    Department of Pharmacy Practice, Bernard J Dunn School of Pharmacy, Shenandoah University, Winchester, VA 22601, USA
    Ann Pharmacother 41:427-32. 2007
    ..Nesiritide may attenuate the body's neurohormonal response to myocardial stretch after CABG and provide clinical benefit in the immediate postoperative period...
  79. ncbi C-type natriuretic peptide hyperpolarizes and relaxes human penile resistance arteries
    Attila Kun
    Department of Pharmacology and Pharmacotherapy, University of Szeged, Szeged, Hungary
    J Sex Med 5:1114-25. 2008
    ..Recently, it has been shown that C-type natriuretic peptide (CNP) shows the characteristics of EDHF in systemic small arteries...
  80. doi Novel agents in cystic fibrosis
    Shane Storey
    Nat Rev Drug Discov 7:555-6. 2008
  81. ncbi Benefit-risk assessment of nesiritide in the treatment of acute decompensated heart failure
    Clyde W Yancy
    Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Texas 75246, USA
    Drug Saf 30:765-81. 2007
    ..When used for approved indications and according to recommended dosage and administration regimens, nesiritide represents a reasonable treatment adjunct for ADHF...
  82. ncbi Hemodynamic effects and safety of nesiritide in neonates with heart failure
    Janet M Simsic
    Sibley Heart Center Cardiology Children s Healthcare of Atlanta, 2835 Brandywine Road, Atlanta, GA 30341, USA
    J Intensive Care Med 23:389-95. 2008
    ..Evaluate effects and safety of nesiritide (Natrecor, Scios Inc.) human B-type natriuretic peptide, in neonates with heart failure...
  83. ncbi Standardizing care for acute decompensated heart failure in a large megatrial: the approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF)
    Justin A Ezekowitz
    University of Alberta, Edmonton, Canada
    Am Heart J 157:219-28. 2009
    ..This review provides key practical information regarding the current standard of care for patients with ADHF including the goals of therapy, management of acute and chronic medications, and discharge/transition of care planning...
  84. ncbi Rationale, design, and methods for the Transplant-Eligible MAnagement of Congestive Heart Failure (TMAC) trial: a multicenter clinical outcomes trial using nesiritide for TMAC
    Mandeep R Mehra
    University of Maryland School of Medicine, Baltimore, MD 21201 1595, USA
    Am Heart J 153:932-40. 2007
    ....
  85. pmc Molecular and physiological effects of nesiritide
    S Reichert
    University of British Columbia, Vancouver, British Columbia
    Can J Cardiol 24:15B-8B. 2008
    ....
  86. ncbi Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF)
    Adrian F Hernandez
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am Heart J 157:271-7. 2009
    ..However, the effect of nesiritide on dyspnea at 6 or 24 hours is unknown, and no clinical outcome trials have been done to provide a reliable estimate of the effect of nesiritide on morbidity and mortality...
  87. ncbi Intracellular signaling pathways involved in inhibition of PAI-1 expression by CNP in endothelial cells
    H Jerczynska
    Department of Molecular and Medical Biophysics, Medical University in Lodz, Lodz, Poland
    Regul Pept 155:150-5. 2009
    ..These data suggest that CNP might function as the natural defense of vascular wall against cytokine induced PAI-1 release through its ability to inactivate PI3K/AKT and MEK/ERK pathways...
  88. ncbi Natriuretic peptides as regulatory mediators of secretory activity in the digestive system
    Maria Eugenia Sabbatini
    Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI 48109 5622, United States
    Regul Pept 154:5-15. 2009
    ..Overall, these findings indicate that ANP and CNP are members of the large group of regulatory peptides affecting digestive secretions...
  89. ncbi Nesiritide enhances myocardial protection during the revascularization of acutely ischemic myocardium
    Harold L Lazar
    Department of Cardiothoracic Surgery, Boston Medical Center, Boston, MA 02118, USA
    J Card Surg 24:600-5. 2009
    ..This study was, therefore, undertaken to determine whether nesiritide alone could enhance myocardial protection when given intraoperatively in a porcine model simulating urgent coronary artery bypass graft surgery...
  90. ncbi [The role of vitamin D in the development of cardiac failure]
    Boglárka Szabó
    Semmelweis Egyetem, Általános Orvostudományi Kar, Kardiológiai Központ, Budapest
    Orv Hetil 150:1397-402. 2009
    ..In spite of the robust preclinical data only few clinical observations prove the positive effect of vitamin D on congestive heart failure...
  91. pmc Atrial natriuretic peptide and renal dopaminergic system: a positive friendly relationship?
    Marcelo Roberto Choi
    Department of Pathophysiology, Faculty of Pharmacy and Biochemistry, University of Buenos Aires, CONICET, INFIBIOC, 1113 Buenos Aires, Argentina
    Biomed Res Int 2014:710781. 2014
    ....
  92. ncbi Brain natriuretic peptide improves long-term functional recovery after acute CNS injury in mice
    Michael L James
    Department of Anesthesiology, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Neurotrauma 27:217-28. 2010
    ..hBNP improves neurological function in murine models of TBI and ICH, and was associated with enhanced CBF and downregulation of neuroinflammatory responses. hBNP may represent a novel therapeutic strategy after acute CNS injury...
  93. ncbi Efficacy and safety of nesiritide in patients with acute decompensated heart failure
    Tracy A Dewald
    Division of Clinical Pharmacology, Duke University Medical Center, Box 3943 Medical Center, Durham, NC 27710, USA
    Expert Rev Cardiovasc Ther 8:159-69. 2010
    ..However, the pathophysiology of acute decompensated heart failure is complex and the impact of nesiritide on important clinical end points, beyond symptomatic and hemodynamic improvement, is unknown...
  94. ncbi Are extracellular osmolality and sodium concentration determined by Donnan effects of intracellular protein charges and of pumped sodium?
    Sven Kurbel
    Department of Physiology, Osijek Medical Faculty, J Huttlera 4, 31000 Osijek, Croatia
    J Theor Biol 252:769-72. 2008
    ..Individual cells can reduce eventual residual osmotic forces on their membrane through altering cell volume by chloride shift, and by modulating the Na+K+-ATPase function...
  95. ncbi [The best of clinical pharmacology in 2002]
    M Andrejak
    Service de Pharmacologie Clinique, CHU, Hopital Sud, 80054 Amiens
    Arch Mal Coeur Vaiss 96:41-50. 2003
    ..Finally, 2002 was marked by the publication of the WHI study which intensified suspicions regarding hormonal substitution treatment, confirming the advantage of not only secondary but perhaps primary cardiovascular prevention...
  96. ncbi Turn back the tide of cardiogenic pulmonary edema
    Marcia Bixby
    Beth Israel Deaconess Medical Center, Boston, MA, USA
    Nursing 35:56-60; quiz 60-1. 2005
  97. ncbi Evaluating ventricular function with B-type natriuretic peptide in obstetric patients
    John J Folk
    Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, State University of New York Upstate Medical University, Syracuse, New York 13210, USA
    J Reprod Med 50:147-54. 2005
    ..To determine if a rapid serum assay for B-type natriuretic peptide (BNP) provides information regarding ventricular function in obstetric patients with acute dyspnea...
  98. ncbi Mouse natriuretic peptide receptor 3 gene maps to proximal chromosome 15
    O V Savinova
    Jackson Laboratory, Bar Harbor, Maine 04609, USA
    Mamm Genome 8:788. 1997
  99. ncbi Blood pressure and endocrine responses of healthy subjects in cold pressor test after acutely increased dietary sodium intake
    O Arjamaa
    Center of Arctic Medicine, University of Oulu, Oulu, Finland
    J Physiol Anthropol Appl Human Sci 20:207-12. 2001
    ..To conclude, acutely increased sodium intake does not change blood pressure or hormonal responses in a cold pressor test in young healthy subjects...
  100. ncbi Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine
    David J Wang
    Department of Medicine, University of Maryland School of Medicine, and Baltimore Veterans Administration Medical Center, USA
    Circulation 110:1620-5. 2004
    ..However, studies of brain natriuretic peptide in patients with heart failure have come to conflicting conclusions about effects on glomerular filtration rate (GFR), effective renal plasma flow, natriuresis, and diuresis...
  101. ncbi [Cardiovascular abnormalities as a cause of hypertension]
    H Takano
    Department of Medicine III, Chiba University School of Medicine
    Nippon Rinsho 59:867-71. 2001
    ..On the other hand, vasodilator neurohumoral factors such as natriuretic peptides and adrenomedulin inhibit VSMCs proliferation. Both neurohumoral factors mutually interact and develop hypertension...

Research Grants26

  1. Physiological Regulation of MLCK in Intact Arteries
    Withrow Gil Wier; Fiscal Year: 2013
    ..This research will utilize a mouse model of salt-induced hypertension to provide specific new information on the role of MLCK in high blood pressure. ..
  2. SODIUM AND CALCIUM METABOLISM IN PREHYPERTENSIVE STATE
    Vito Campese; Fiscal Year: 1990
    ....
  3. APPROACHES TO NATRIURETIC AND ANTIHYPERTENSIVE AGENTS
    William Wechter; Fiscal Year: 2001
    ....
  4. REPRODUCTIVE ENDOCRINOLOGY OF CNS ATRIAL PEPTIDES
    WILLIS SAMSON; Fiscal Year: 1990
    ....
  5. ACTION - A CHF Trial Investigating Outcomes of Exercise
    CHRISTOPHER O CONNOR; Fiscal Year: 2008
    ..The trial will take place over 5 years with an initial 6 months for planning, training, and implementation; 3 years of enrollment; 1 year of follow-up; and 6 months for close out, analysis, and presentation. ..
  6. NO AND OXIDATIVE STRESS IN HUMAN MYOCARDIAL FAILURE
    Michael Givertz; Fiscal Year: 2003
    ..abstract_text> ..
  7. SCHOLARS IN CLINICAL SCIENCE PROGRAM
    Gordon Williams; Fiscal Year: 2004
    ..abstract_text> ..
  8. Inflammation & Prognosis in Decompensated Heart Failure
    GARY FELKER; Fiscal Year: 2008
    ..Felker's development into an established independent clinical investigator with expertise in both complex clinical research methodology and the role of inflammation in the pathophysiology of heart failure. ..
  9. Non-Modulation Phenotype and Vascular Dysfunction in Diabetes Mellitus
    Gordon H Williams; Fiscal Year: 2010
    ....
  10. Na,K-ATPase alpha4 isoform in male germ cell physiology
    V GUSTAVO BLANCO; Fiscal Year: 2010
    ..abstract_text> ..
  11. ISOLATED DIASTOLIC DYSFUNCTION
    MARGARET REDFIELD; Fiscal Year: 2008
    ....
  12. Aldosterone, Histone Demethylase and Cardiovascular Disease
    Gordon H Williams; Fiscal Year: 2010
    ..This project is designed to assess one of those mechanisms thereby providing entrie to developing more directed therapy to treat cardiovascular diseases. ..
  13. CHF TRIAL INVESTIGATING OUTCOMES OF EXERCISE TRAINING
    Dalane Kitzman; Fiscal Year: 2007
    ..abstract_text> ..
  14. Mechanisms of Aldosterone Induced Cardiovascular Damage
    Gordon Williams; Fiscal Year: 2006
    ..Our results should better define the rationale for the use of mineralocorticoid receptor antagonists to prevent damage to the heart and other tissues when ALDO levels are inappropriate relative to Na intake. ..
  15. Decision Making in End-Stage Heart Failure
    Paul Hauptman; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  16. VASCULAR DISEASE IN HBP--ANGII, PAI1, INSULIN AND GENES
    Gordon Williams; Fiscal Year: 2001
    ..With this information, specific preventive and therapeutic measures to retard the development of these complications could be proposed and tested in a clinical trial's format. ..
  17. PREDICTING AND IMPROVING OUTCOMES IN ACUTE RENAL FAILURE
    Ravindra Mehta; Fiscal Year: 2001
    ..It is anticipated (by the applicants) that information gained from this study, being largely observational, will be used to rationally design intervention strategies in future years. ..
  18. ACTION-A CHF TRIAL INVESTIGATING OUTCOMES OF EXERCISE
    William Abraham; Fiscal Year: 2005
    ..The trial will take place over 5 years with an initial 6 months for planning, training, and implementation; 3 years of enrollment; 1 year of follow-up; and 6 months for close out, analysis, and presentation. ..
  19. Septate junctional proteins: Proteomic identification and role in diuresis
    KLAUS BEYENBACH; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  20. EXERCISE INTOLERANCE IN ELDERLY DIASTOLIC HEART FAILURE
    Dalane Kitzman; Fiscal Year: 2004
    ..abstract_text> ..
  21. Cyclic GMP And Ventricular Function In Heart Failure
    MARGARET REDFIELD; Fiscal Year: 2003
    ..abstract_text> ..